| abstract |
The present invention provides compounds and methods for inhibiting proteases. One aspect of the invention features a prosoft inhibitor that reacts with an activated protease and releases an active inhibitor component in the vicinity of the target protease. In certain instances, the compound inhibits proteasomes such as dipeptidyl peptidase IV and / or post-proline cleaving enzyme (PPCE). The compounds of the present invention provide better therapeutic indices in part due to reduced toxicity and / or improved specificity for the target protease. Another aspect of the invention is for treating type II diabetes, insulin resistance, impaired glucose tolerance, hyperglycemia, hypoglycemia, hyperinsulinemia, obesity, hyperlipidemia, or hyperlipoproteinemia. Provided for use of the compounds of the present disclosure. |